Eledon Pharmaceuticals is focused on advancing innovative therapies aimed at improving outcomes for organ transplant recipients, particularly through their lead compound, tegoprubart. This anti-CD40L antibody is designed to modulate the immune response, potentially reducing the risk of organ rejection and enhancing the longevity of transplanted organs. Eledon is currently conducting clinical trials, including the BESTOW trial, which is a Phase 2 study comparing tegoprubart to standard immunosuppressive therapies in kidney transplant patients. The goal is to demonstrate superior kidney function and safety profiles, thereby addressing the significant challenges faced by transplant recipients, such as the side effects of traditional immunosuppressants and the high rates of graft failure.

In addition to kidney transplantation, Eledon is exploring the application of tegoprubart in other organ transplant scenarios, including liver transplantation and xenotransplantation. The company aims to tackle the longstanding issues in transplant medicine, where innovation has been limited for decades. By targeting the CD40 Ligand pathway, Eledon seeks to provide a more effective means of controlling immune responses, ultimately leading to better transplant durability and improved quality of life for patients. Their commitment to the mission of "One Transplant for Life" underscores their dedication to enhancing the transplant experience and outcomes for patients.

United States

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Endocrine System Diseases

Immune System Diseases

Kidney Diseases

Metabolic Diseases

Nervous System Diseases

Eledon Pharmaceuticals

Kidney transplantation

T-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for &nbsp;CD40L (also called CD154), a well-validated biological target with &nbsp;broad therapeutic potential. It was built around safety and engineered &nbsp;to maximize efficacy and half life.
Importantly, AT-1501 targets &nbsp;CD40L (also called CD154), not the CD40 receptor.&nbsp;Blocking CD40L &nbsp;inhibits both CD40 and CD11 costimulatory signaling pathways with the &nbsp;potential for better efficacy. Blocking CD40L also increases &nbsp;polarization of lymphocytes to Tregs, creating a more tolerogenic &nbsp;environment, which provides the potential for better efficacy. CD40L is &nbsp;more selectively expressed than the CD40 receptor, thus the potential &nbsp;for improved safety, as well as pharmacokinetic, pharmacodynamic, and &nbsp;dosing advantages.
<a href="https://eledon.com/research-and-development/at-1501_anti-cd40l-antibody/">Source</a>

Tegoprubart (AT-1501)

Islet Cell Transplantation

Type 1 diabetes

Amyotrophic lateral sclerosis

IgA nephropathy

AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for &nbsp;CD40L (also called CD154), a well-validated biological target with &nbsp;broad therapeutic potential. It was built around safety and engineered &nbsp;to maximize efficacy and half life.
Importantly, AT-1501 targets &nbsp;CD40L (also called CD154), not the CD40 receptor.&nbsp;Blocking CD40L &nbsp;inhibits both CD40 and CD11 costimulatory signaling pathways with the &nbsp;potential for better efficacy. Blocking CD40L also increases &nbsp;polarization of lymphocytes to Tregs, creating a more tolerogenic &nbsp;environment, which provides the potential for better efficacy. CD40L is &nbsp;more selectively expressed than the CD40 receptor, thus the potential &nbsp;for improved safety, as well as pharmacokinetic, pharmacodynamic, and &nbsp;dosing advantages.
<a href="https://eledon.com/research-and-development/at-1501_anti-cd40l-antibody/">Source</a>

Eledon Pharmaceuticals

Company Details